CROSS-SPECIES EXTRAPOLATIONS AND THE BIOLOGIC BASIS FOR SAFETY FACTOR DETERMINATIONS IN DEVELOPMENTAL TOXICOLOGY

[1] COMPARATIVE REQUIREMENTS FOR PRE-MARKETING PREMANUFACTURE NOTIFICATIONS IN THE EC COUNTRIES AND THE USA, WITH SPECIAL REFERENCE TO RISK ASSESSMENT IN THE FRAMEWORK OF THE US TOXIC-SUBSTANCES CONTROL ACT (TSCA) [J]. JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY, 1983, 2 (01): : 131 - 145

[2] BASS R, 1976, ADV DETECTION CONGEN, P198

[3] BASS R, 1975, NEW APPROACHES EVALU, P524

[4] PROTECTING PUBLIC FROM TERATOGENIC AND MUTAGENIC HAZARDS [J]. JOURNAL OF CLINICAL PHARMACOLOGY AND NEW DRUGS, 1972, 12 (2-3): : 61 - &

[5] Butcher R. E., 1975, ABERRANT DEV INFANCY, P161

[6] CHAO ST, 1983, TERATOGENESIS REPROD

[7] CHRISTIAN MS, 1983, TERATOGENESIS REPROD

[8] Dourson M L, 1983, Regul Toxicol Pharmacol, V3, P224, DOI 10.1016/0273-2300(83)90030-2

[9] FABRO S, 1982, TERATOGEN CARCIN MUT, V2, P61, DOI 10.1002/1520-6866(1990)2:1<61::AID-TCM1770020107>3.0.CO

[10] 2-O

[1] COMPARATIVE REQUIREMENTS FOR PRE-MARKETING PREMANUFACTURE NOTIFICATIONS IN THE EC COUNTRIES AND THE USA, WITH SPECIAL REFERENCE TO RISK ASSESSMENT IN THE FRAMEWORK OF THE US TOXIC-SUBSTANCES CONTROL ACT (TSCA) [J]. JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY, 1983, 2 (01): : 131 - 145

[2] BASS R, 1976, ADV DETECTION CONGEN, P198

[3] BASS R, 1975, NEW APPROACHES EVALU, P524

[4] PROTECTING PUBLIC FROM TERATOGENIC AND MUTAGENIC HAZARDS [J]. JOURNAL OF CLINICAL PHARMACOLOGY AND NEW DRUGS, 1972, 12 (2-3): : 61 - &

[5] Butcher R. E., 1975, ABERRANT DEV INFANCY, P161

[6] CHAO ST, 1983, TERATOGENESIS REPROD

[7] CHRISTIAN MS, 1983, TERATOGENESIS REPROD

[8] Dourson M L, 1983, Regul Toxicol Pharmacol, V3, P224, DOI 10.1016/0273-2300(83)90030-2

[9] FABRO S, 1982, TERATOGEN CARCIN MUT, V2, P61, DOI 10.1002/1520-6866(1990)2:1<61::AID-TCM1770020107>3.0.CO

[10] 2-O